Blue Jet Healthcare Limited
Blue Jet Healthcare Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹293 cr of revenue in its latest quarter (Q1 FY27) and kept 26.7% of sales as profit.
“Growing with Purpose. Scaling with Partners. We are a leading specialty pharmaceutical and healthcare ingredient company and an end-to-end integrated Contract Development and Manufacturing Organisation (CDMO), underpinned by trusted relationships, complex chemistry, and a relentless focus on shared growth.”
“is to be integrated We commit ourselves to Quality growth partner of choice in customer delight by delivering Integrity Global Pharmaceutical and quality products and services.”
Healthier than 79% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 134–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 45
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in BLUEJET?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own revenue trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹293 cr |
| Other Income | ₹15 cr |
| Total Income | ₹308 cr |
| Cost of Materials | ₹179 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Inventory Change (±) | ₹-42 cr |
| Employee Benefit Expense | ₹20 cr |
| Finance Costs | ₹66 L |
| Depreciation & Amortisation | ₹7 cr |
| Other Expenses | ₹38 cr |
| Total Expenses | ₹202 cr |
| Profit before Tax | ₹106 cr |
| Tax Expense | ₹28 cr |
| Net Profit | ₹78 cr |
| Net margin on total income | 25.4% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 192 cr | 235 cr | 293 cr |
| Total income | 206 cr | 258 cr | 308 cr |
| Expenses | 152 cr | 170 cr | 202 cr |
| Profit before tax | 54 cr | 87 cr | 106 cr |
| Tax | 14 cr | 23 cr | 28 cr |
| Net profit (owners' share) | 40 cr | 64 cr | 78 cr |
| Net margin (owners' share, on revenue) | 20.9% | 27.4% | 26.7% |
| EPS (₹) | 2.32 | 3.71 | 4.51 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.2 / share | 11 Sep 2026 |
| Dividend | ₹1.2 / share | 19 Sep 2025 |
| Dividend | ₹1 / share | 17 Sep 2024 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.